– Shock Absorber for the Knee Targets Patients Who Are Seeking Alternatives to Joint Replacement HAYWARD, Calif. – Moximed®, Inc. announced today that the first patient has been treated in an FDA-approved IDE study for its latest generation unicompartmental unloading implant, the Atlas…
– Topline data to be presented today at NACFC LEIDEN, the Netherlands (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that clinical study PQ-010-002, a proof-of-concept study of nasal potential difference (NPD), demonstrated that QR-010 restored CFTR function…
– San Diego, USA and Palma, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced successful initiation of the first clinical trial of its lead candidate, SNF472, for the treatment of the orphan…
– Funding will be used to support go-to-market activities in Europe BARCELONA – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its…
– Acacia Pharma announces positive results from a pivotal Phase 3 trial of BAREMSIS™ for the treatment of post-operative nausea and vomiting BAREMSIS now shown to treat PONV, as well as prevent it Cambridge, UK – Acacia Pharma Group plc ("Acacia Pharma"), the supportive care company…
– Equity Offering to Support Heart Failure Trial and European Commercial Expansion Minneapolis – CVRx, Inc., a private medical device company, has announced an equity financing totaling $93 million. Gilde Healthcare participated in the financing alongside existing investors, Johnson…
– Board will be strengthened with industry experts and Enrique Vega appointed as new CEO Mont-Saint-Guibert, Belgium – Nyxoah S.A., a medical device company focused on developing a neurostimulation based, disruptive therapy for patients suffering from Obstructive Sleep Apnea (OSA),…
– NightBalance raises EUR 12.5 million to support the commercial roll-out of the Sleep Position Trainer in Europe and the U.S. Supervisory Board and Management team strengthened with industry experts Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep…
– Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO CMO appointment and launch of US subsidiary are significant steps in establishing a US presence Palma de Mallorca, Spain - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical…
– Results from Multi-center, Prospective Study with Unicompartmental Joint Unloading Device for the Knee Presented at ESSKA / Moximed Commercializing Atlas System in Europe
– Agendia, Inc. announced that using the company's MammaPrint® assay, patients with early-stage breast cancer who were considered at high risk for disease recurrence based on clinical and biological criteria can avoid chemotherapy.
– Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling EUR 25 million. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system.
– Acacia Pharma Group announces the initiation of its second pivotal Phase 3 treatment study, investigating BAREMSIS™ in surgical patients who develop post-operative nausea & vomiting, despite having received antiemetic prophylaxis before surgery.
– Ede, The Netherlands - NIZO food research, an international contract research organization (CRO) for companies active in food and healthcare markets, announces today that Gilde Healthcare has joined as a shareholder to facilitate long term growth. Jasper van Gorp, Managing Partner…
– SAN DIEGO, Calif. – ResMed (NYSE:RMD), a leading innovator in sleep-disordered breathing and respiratory care, today announced it has entered into a definitive agreement to acquire Inova Labs Inc., a privately-held medical device company specializing in the development and commercialization…
– Cambridge, UK – Acacia Pharma Group plc, the supportive care company developing products for US and international markets, announces positive results from a Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) in combination with standard antiemetics for…
– Partnership aims to advance development of novel immune checkpoint therapies as Baxalta expands oncology leadership in orphan diseases Symphogen to receive $175 million (€160 million) upfront, in addition to potential future milestone payments and royalties BANNOCKBURN, Ill. and…